Veritable L.P. boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,244 shares of the medical research company’s stock after purchasing an additional 71 shares during the quarter. Veritable L.P.’s holdings in Edwards Lifesciences Corporation were worth $738,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in EW. Shine Investment Advisory Services Inc. acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at about $126,000. Cornerstone Advisors Inc. raised its stake in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares during the last quarter. Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares during the last quarter. Captrust Financial Advisors acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at about $149,000. Finally, Johnson Financial Group Inc. raised its stake in Edwards Lifesciences Corporation by 7.1% in the 2nd quarter. Johnson Financial Group Inc. now owns 1,639 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 109 shares during the last quarter. 82.08% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation (NYSE:EW) opened at 109.31 on Friday. The firm has a 50-day moving average price of $113.80 and a 200-day moving average price of $109.37. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The stock has a market cap of $23.08 billion, a PE ratio of 33.15 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. During the same period last year, the business earned $0.76 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

In related news, VP Donald E. Bobo, Jr. sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Insiders sold a total of 176,901 shares of company stock worth $20,191,196 over the last three months. 2.13% of the stock is owned by company insiders.

Several research analysts recently weighed in on EW shares. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. BMO Capital Markets reissued a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Cowen and Company reissued an “outperform” rating and issued a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and an average target price of $120.75.

COPYRIGHT VIOLATION NOTICE: “Veritable L.P. Has $738,000 Position in Edwards Lifesciences Corporation (EW)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/30/veritable-l-p-has-738000-position-in-edwards-lifesciences-corporation-ew.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.